Featured Research

from universities, journals, and other organizations

A single protein helps the body keep watch over the Epstein-Barr virus

Date:
February 17, 2012
Source:
Children's Hospital Boston
Summary:
Some 90 percent of people are exposed to the Epstein Barr virus at some point in their life. Even though it is quickly cleared from the body, the virus can linger silently for years in small numbers of infected B cells. According to researchers, the immune system subdues the virus by watching for a single viral protein called LMP1.

Some 90 percent of people are exposed to the Epstein Barr virus (EBV) at some point in their life. Even though it is quickly cleared from the body, the virus can linger silently for years in small numbers of infected B cells. According to researchers at Children's Hospital Bostonand the Immune Disease Institute (IDI), the immune system subdues the virus by watching for a single viral protein called LMP1, knowledge that has already helped suggest two new treatments for the EBV-fueled cancers seen in some immunosuppressed patients.

The study team, led by Klaus Rajewksy, MD, and Baochun Zhang, MD, PhD, of the Program in Cellular and Molecular Medicine at Children Hospital Boston and the IDI, reported their results online this week in the journal Cell.

While the immune system's T cells rapidly clear most EBV-infected B cells, about one in a million infected cells escapes destruction. Within these cells, the virus enters a latent phase, kept in check by the watchful eye of so-called memory T cells. This uneasy relationship usually holds steady the rest of a person's life, unless something -- such as infection with HIV or use of anti-rejection drugs following a transplant -- suppresses the immune system and breaks the surveillance. The virus can then reawaken and drive the development of B cell cancers like AIDS-associated B cell lymphoma and post-transplant lymphoproliferative disorder.

To better understand how the immune system maintains its watch and how the virus turns cells cancerous, Rajewsky and his team had generated a model mimicking latent EBV infection by engineering mice whose B cells contained an inducible version of viral LMP1. Researchers have long known that EBV needs LMP1 to turn B cells cancerous, but modeling this relationship in vivo had proven challenging.

"We had previously attempted to develop an animal model of LMP1 transformation of B cells," said Rajewsky, who recently moved to the Max Delbrück Center for Molecular Medicinein Germany, "but we had never been able to get the mice in our models to actually produce any mature B cells. The immune response against the LMP1-producing B cells was so robust that the cells were eliminated very early on."

Their breakthrough came when Zhang and colleagues reengineered the model to lack T cells. "The mice were initially fine, but succumbed within two to three months to aggressive B cell lymphomas," Rajewsky said. "The profile mimicked very closely what we see in immunosuppressed lymphoma patients." In additional experiments with Rajewsky's original model, the team eliminated the mice's T cells before activating the viral protein in B cells, sparking a similar but even more rapid fatal disease.

The team also made several observations with possible clinical application. First, they noted that in the mouse model the LMP1 producing B cells were being attacked by a specific kind of T cell called a CD4+ T cell. "Transplant patients who develop B cell lymphomas because they are immunosuppressed by their anti-rejection drugs are often treated with T cells that carry the CD8 marker," Rajewsky noted. "These results would argue for also considering CD4+ T cells for treatment."

Second, they found that tumors in the LMP1 producing mice often displayed targets recognized by another kind of immune cell called a natural killer (NK) cell. Seeing an opportunity, Rajewsky worked with cancer immunologist Glenn Dranoff, MD and colleagues at Dana-Farber Cancer Institute, to test a potential therapeutic agent that uses a portion of the NK cell activating receptor called NKG2D,fused to the stimulatory Fc portion of an antibody, a combination capable of activating and directing immune attack against tumor cells. In a transplantation model of LMP1-fueled lymphomas, the NKG2D-Fc fusion proved quite capable of reducing tumor growth and prolonging survival of the recipients.

"These preclinical results suggest administration of the NKG2D-Fc fusion protein, perhaps combined withtreatment with CD4+ T cells, could benefit some patients with EBV-driven lymphomas," Rajewsky said. "What we can say with certainty, though, is that LMP1 is the immune system's primary surveillance trigger following EBV infection and clearance, knowledge that we think will open doors to additional treatment options."

This study was supported by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, the Leukemia and Lymphoma Society, the Japan Society for the Promotion of Science, and the Astellas Foundation for Research on Metabolic Disorders.


Story Source:

The above story is based on materials provided by Children's Hospital Boston. Note: Materials may be edited for content and length.


Journal Reference:

  1. Baochun Zhang, Sven Kracker, Tomoharu Yasuda, Stefano Casola, Matthew Vanneman, Cornelia Hömig-Hölzel, Zhe Wang, Emmanuel Derudder, Shuang Li, Tirtha Chakraborty, Shane E. Cotter, Shohei Koyama, Treeve Currie, Gordon J. Freeman, Jeffery L. Kutok, Scott J. Rodig, Glenn Dranoff, Klaus Rajewsky. Immune Surveillance and Therapy of Lymphomas Driven by Epstein-Barr Virus Protein LMP1 in a Mouse Model. Cell, 2012; 148 (4): 739 DOI: 10.1016/j.cell.2011.12.031

Cite This Page:

Children's Hospital Boston. "A single protein helps the body keep watch over the Epstein-Barr virus." ScienceDaily. ScienceDaily, 17 February 2012. <www.sciencedaily.com/releases/2012/02/120217145623.htm>.
Children's Hospital Boston. (2012, February 17). A single protein helps the body keep watch over the Epstein-Barr virus. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2012/02/120217145623.htm
Children's Hospital Boston. "A single protein helps the body keep watch over the Epstein-Barr virus." ScienceDaily. www.sciencedaily.com/releases/2012/02/120217145623.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) — America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) — A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:  

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile iPhone Android Web
          Follow Facebook Twitter Google+
          Subscribe RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins